Celldex Therapeutics (CLDX) Common Equity (2010 - 2026)

Celldex Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $456.2 million for Q1 2026.

• In Q1 2026, Common Equity fell 35.1% year-over-year to $456.2 million; the TTM figure through Mar 2026 stood at $456.2 million (down 35.1% YoY), while the FY2025 annual figure was $527.2 million, down 29.43% from the prior year.
• Common Equity was $456.2 million for Q1 2026 at Celldex Therapeutics, down from $527.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $838.6 million in Q1 2024 to a low of $246.7 million in Q3 2023.
• Historically, Common Equity has averaged $518.6 million across 5 years, with a median of $456.2 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Common Equity surged 218.54% in 2024, then plunged 35.1% in 2026.
• A 5-year view of Common Equity shows it stood at $326.2 million in 2022, then surged by 31.57% to $429.2 million in 2023, then jumped by 74.06% to $747.0 million in 2024, then declined by 29.43% to $527.2 million in 2025, then retreated by 13.46% to $456.2 million in 2026.
• The last three Common Equity figures came in at $456.2 million (Q1 2026), $527.2 million (Q4 2025), and $598.4 million (Q3 2025), per Business Quant data.